-
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit with a PD-1 or PD-L1 ...
Exact
Phase N/A
-
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA ...
The purpose of this study is to test the good and bad effects of the study drugs called nivolumab and ...Exact
Phase N/A
-
A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients With Advanced Solid ...
This is a Phase 1, open label, multi-center study of orally administered DSP-0337 in adult subjects with advance solid tumors ...Exact
Phase N/A
-
A Phase 1 First-in-Human Open-label Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of AMG 510 in Subjects With Advanced ...
This research study is being done to test the effects of a new investigational drug therapy called AMG 510 which ...Exact
Phase N/A
-
eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient ...
This study will evaluate the safety, tolerability, antitumor activity, and pharmacokinetics (PK) of eFT508 in patients who have initiated anti-PD-1 ...Exact
Phase N/A
-
A Phase II study of Concurrent Chemoradiation plus Durvalumab (MEDI4736) followed by Surgery followed by Adjuvant Durvalumab (MEDI4736) in medically ...
The purpose of this study is to estimate the pathological complete response rate at the time of surgery in patients ...
Exact
-
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD- ...
This study is being done in subjects with advanced and/or metastatic solid tumors. The treatment-specific Module A portion of ...
Exact
Showing - of studies